CHF Solutions (NASDAQ:CHFS) Releases Earnings Results, Misses Expectations By $0.47 EPS

CHF Solutions (NASDAQ:CHFS) announced its quarterly earnings data on Tuesday. The company reported ($1.93) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.46) by ($0.47), Morningstar.com reports. CHF Solutions had a negative net margin of 336.26% and a negative return on equity of 188.60%. The firm had revenue of $1.68 million during the quarter.

NASDAQ CHFS traded up $0.07 during trading hours on Wednesday, reaching $2.49. The company had a trading volume of 88,598 shares, compared to its average volume of 133,521. The company has a market capitalization of $5.68 million, a PE ratio of -0.06 and a beta of 2.37. CHF Solutions has a 1-year low of $2.15 and a 1-year high of $20.02. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.86 and a quick ratio of 5.12. The firm has a 50-day moving average price of $2.88.

CHFS has been the topic of a number of recent analyst reports. Zacks Investment Research cut shares of CHF Solutions from a “hold” rating to a “sell” rating in a research report on Monday, July 8th. ValuEngine raised shares of CHF Solutions from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.

An institutional investor recently bought a new position in CHF Solutions stock. Virtu Financial LLC purchased a new position in shares of CHF Solutions Inc (NASDAQ:CHFS) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 14,140 shares of the company’s stock, valued at approximately $58,000. Virtu Financial LLC owned approximately 2.76% of CHF Solutions as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 10.17% of the company’s stock.

CHF Solutions Company Profile

CHF Solutions, Inc, a medical device company, focuses on the provision of solutions for patients suffering from fluid overload. The company's commercial product is the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

Further Reading: What is the G-20?

Earnings History for CHF Solutions (NASDAQ:CHFS)

Receive News & Ratings for CHF Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CHF Solutions and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit